Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Increased tetrahydrobiopterin (BH4) generated in injured sensory neurons contributes to increased pain sensitivity and its persistence.

GTP cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the de novo BH4 synthetic pathway, and human single-nucleotide polymorphism studies, ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

A peripherally restricted form of fluphenazine that abrogates pathologically elevated GCH1 and BH4 in peripheral neurons after injury or inflammation could ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer · Overview · Fingerprint ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Journal article · Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer · Email ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. @article ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Shane J.F. Cronin ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. 表型药物筛选揭示代谢 ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Cronin SJF et al.

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway ...

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Cronin, S.J.F.; Rao, S ...

Old Cancer Drugs Hint at New Ways to Beat Chronic Pain

Original Research: Closed access. “Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated ...

Old drugs hint at new ways to beat chronic pain | ScienceDaily

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.

Old drugs hint at new ways to beat chronic pain

Cronin, S. J. F., et al., “Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic ...

Search results - ORA - Oxford University Research Archive

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.

Dysregulated BH4 metabolism facilitates immunosuppression in ...

7. Cronin, S.J.F. ∙ Rao, S. ∙ Tejada, M.A. ... Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS- ...

GCH1 variants, tetrahydrobiopterin and their effects on pain sensitivity

... (GCH1) involved in the biosynthetic pathway of tetrahydrobiopterin (BH4). This ... Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key ...

New role for GCH1 in cancer - Cronin

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Sci Transl Med 2022 ...

Publications | Woolf Laboratory - FM Kirby Neurobiology Center

2022 Science Translational Medicine. Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain ...

Science, Medicine, and the Anesthesiologist - ASA Publications

Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Sci Transl Med 2022 ...